Hemogenyx Pharmaceuticals
HEMO · Main Market · Health Care · mcap £48m · 735.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | Routine | Total Voting Rights | |
| 28 Sep 26 | Results | Half-year Results
Interim Results for the period ended 30 June 2026 |
+3.2% |
| 03 Sep 26 | Exercise of Warrants and Issue of Equity
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received notices to exercise warrants over 96,825 new ordinary shares in the Company (the "Warrant Shares"). |
+6.9% | |
| 11 Aug 26 | Collaboration with Cellin Technologies
Hemogenyx Pharmaceuticals Signs Definitive Collaboration Agreement with Cellin Technologies for Manufacturing and Commercialization of HG-CT-1 CAR-T Therapy in Estonia |
+1.9% | |
| 29 Jul 26 | Collaboration and Company Update
Collaboration with Vilnius University Hospital Santaros Klinikos on HG-CT-1 Clinical Application and Research |
−8.5% | |
| 01 Jul 26 | Routine | Result of AGM | |
| 05 Jun 26 | Routine | Notice of AGM | |
| 29 May 26 | Routine | Grant of Options and Extension of Warrant Term | |
| 30 Apr 26 | Results | Final Results
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2025. |
−0.7% |
| 28 Apr 26 | Fundraise | Institutional Fundraise
Hemogenyx Secures £3,000,000 to accelerate its Phase 1 Clinical Trials and initiate early commercialization of HG-CT-1 |
−14.1% |
| 14 Apr 26 | Annual IND Report with FDA
Hemogenyx Pharmaceuticals Files Annual IND Report with FDA for HG-CT-1 CAR-T Therapy for AML |
−11.4% | |
| 31 Mar 26 | Tech Transfer Completion and Clinical Trial Update
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a biopharmaceutical company focused on the development of innovative therapies for the treatment of blood diseases, is pleased to provide the following update on its HG-CT-1 CAR |
+2.1% | |
| 27 Feb 26 | Routine | Total Voting Rights | |
| 24 Feb 26 | Holding | Holding(s) in Company | |
| 23 Feb 26 | Exercise of Warrants and Issue of Equity
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received notices to exercise warrants over 50,841 new ordinary shares in the Company (the "Warrant Shares"). |
+4.7% | |
| 10 Feb 26 | Routine | Issue of Equity - Correction | |
| 10 Feb 26 | Routine | Issue of Equity | |
| 30 Jan 26 | Routine | Total Voting Rights | |
| 12 Jan 26 | Holding | Holding(s) in Company | |
| 22 Dec 25 | Update on Admission of Shares
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update to the admission of new ordinary shares as announced on 18 December 20 |
+6.0% | |
| 18 Dec 25 | Routine | Issue of Equity | |
| 08 Dec 25 | Holding | Holding(s) in Company | |
| 28 Nov 25 | Routine | Total Voting Rights | |
| 19 Nov 25 | Routine | Publication of Prospectus | |
| 29 Oct 25 | Clinical Trial Update and Grant of Share Awards
DSMB Clearance to Proceed to the Next Dose Level of HG-CT-1 in Adult Patients, Opening Pediatric Recruitment, and Grant of Restricted Share Units to Hemogenyx Team |
+4.1% | |
| 06 Oct 25 | Clearance to Initiate Pediatric Enrolment
MD Anderson Clearance to Initiate Pediatric Enrolment in HG-CT-1 Clinical Trial |
+7.9% |
Company filings. Not investment advice.